Disorders of lipid metabolism in the liver in patients with chronic viral hepatitis
- Authors: Tsvetkov V.V.1, Tokin I.I.1,2, Nikitina O.E.1, Lioznov D.A.1,3
-
Affiliations:
- Smorodintsev Research Institute of Influenza
- North-Western State Medical University named after I.I. Mechnikov, Saint Petersburg, Russia
- Pavlov First Saint Petersburg State Medical University
- Issue: Vol 13, No 2 (2021)
- Pages: 27-38
- Section: Reviews
- URL: https://journals.rcsi.science/vszgmu/article/view/71418
- DOI: https://doi.org/10.17816/mechnikov71418
- ID: 71418
Cite item
Abstract
The review article is devoted to the problem of lipid metabolism disorders in the liver in patients with chronic hepatitis B and chronic hepatitis C. The results of modern biological, epidemiological and clinical studies aimed at studying the causes and mechanisms of the formation of liver steatosis and steatohepatitis, their prevalence and influence on the course of infectious pathology are presented. Particular attention is paid to the generalization and systematization of the currently available data on the mechanisms of lipid metabolism disorders in the liver, mediated by the molecular structures of hepatitis B and C viruses. In conclusion, the need for timely diagnosis and treatment of pathological conditions caused by the development of lipid metabolism disorders in the liver is substantiated in order to increase the quality of medical care for patients with chronic hepatitis B and C.
Full Text
##article.viewOnOriginalSite##About the authors
Valeriy V. Tsvetkov
Smorodintsev Research Institute of Influenza
Author for correspondence.
Email: suppcolor@gmail.com
ORCID iD: 0000-0001-5195-9316
SPIN-code: 6562-9851
MD, Cand. Sci. (Med.)
Russian Federation, 15/17 Professor Popova str., Saint-Petersburg, 197376Ivan I. Tokin
Smorodintsev Research Institute of Influenza;North-Western State Medical University named after I.I. Mechnikov, Saint Petersburg, Russia
Email: ivan.tokin@influenza.spb.ru
ORCID iD: 0000-0002-9824-3945
SPIN-code: 2496-9920
MD, Cand. Sci. (Med.)
Russian Federation, 15/17 Professor Popova str., Saint-Petersburg, 197376; 41 Kirochnaya str., Saint Petersburg, 191015Olesya E. Nikitina
Smorodintsev Research Institute of Influenza
Email: olesya.nikitina@influenza.spb.ru
ORCID iD: 0000-0001-5506-9919
SPIN-code: 2478-0403
MD, Cand. Sci. (Med.)
Russian Federation, 15/17 Professor Popova str., Saint-Petersburg, 197376Dmitry A. Lioznov
Smorodintsev Research Institute of Influenza; Pavlov First Saint Petersburg State Medical University
Email: dlioznov@yandex.ru
ORCID iD: 0000-0003-3643-7354
SPIN-code: 3321-6532
MD, Dr. Sci. (Med.)
Russian Federation, 15/17 Professor Popova str., Saint-Petersburg, 197376; Saint-PetersburgReferences
- Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol. 2013;48(4):434–441. doi: 10.1007/s00535-013-0758-5
- Marchesini G, Brizi M, Morselli-Labate A, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107(5):450–455. doi: 10.1016/s0002-9343(99)00271-5
- Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50(8):1844–1850. doi: 10.2337/diabetes.50.8.1844
- Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109(9):1125–1131. doi: 10.1172/jci0215593
- Wang Y, Viscarra J, Kim SJ, Sul HS. Transcriptional regulation of hepatic lipogenesis. Nat Rev Mol Cell Biol. 2015;16(11):678–689. doi: 10.1038/nrm4074
- Walther TC, Farese JrRV. Lipid droplets and cellular lipid metabolism. Annu Rev Biochem. 2012;81:687–714. doi: 10.1146/annurev-biochem-061009-102430
- Wilfling F, Wang H, Haas JT, et al. Triacylglycerol synthesis enzymes mediate lipid droplet growth by relocalizing from the ER to lipid droplets. Dev Cell. 2013;24(4):384–399. doi: 10.1016/j.devcel.2013.01.013
- Xu L, Zhou L, Li P. CIDE proteins and lipid metabolism. Arterioscler Thromb Vasc Biol. 2012;32(5):1094–1098. doi: 10.1161/ATVBAHA.111.241489
- Thiam AR, Farese RVJr, Walther TC. The biophysics and cell biology of lipid droplets. Nat Rev Mol Cell Biol. 2013;14(12):775–786. doi: 10.1038/nrm3699
- Kory N, Thiam AR, Farese RVJr, Walther TC. Protein crowding is a determinant of lipid droplet protein composition. Dev Cell. 2015;34(3):351–363. doi: 10.1016/j.devcel.2015.06.007
- Wu JW, Wang SP, Alvarez F, et al. Deficiency of liver adipose triglyceride lipase in mice causes progressive hepatic steatosis. Hepatology. 2011;54(1):122–132. doi: 10.1002/hep.24338
- Singh R, Cuervo AM. Lipophagy: connecting autophagy and lipid metabolism. Int J Cell Biol. 2012;2012:282041. doi: 10.1155/2012/282041
- Tiwari S, Siddiqi SA. Intracellular trafficking and secretion of VLDL. Arterioscler Thromb Vasc Biol. 2012;32(5):1079–1086. doi: 10.1161/ATVBAHA.111.241471
- Ye J, Li JZ, Liu Y, et al. Cideb, an ER and lipid droplet-associated protein, mediates VLDL lipidation and maturation by interacting with apolipoprotein B. Cell Metab. 2009;9(2):177–190. doi: 10.1016/j.cmet.2008.12.013
- Razi B, Alizadeh S, Omidkhoda A, et al. Association of chronic hepatitis B infection with metabolic syndrome and its components: meta-analysis of observational studies. Diabetes Metab Syndr. 2017;11 Suppl 2:S939–S947. doi: 10.1016/j.dsx.2017.07.020
- Jinjuvadia R, Liangpunsakul S. Association between metabolic syndrome and its individual components with viral hepatitis B. Am J Med Sci. 2014;347(1):23–27. doi: 10.1097/MAJ.0b013e31828b25a5
- Chen JY, Wang JH, Lin CY, et al. Lower prevalence of hypercholesterolemia and hyperglyceridemia found in subjects with seropositivity for both hepatitis B and C strains independently. J Gastroenterol Hepatol. 2010;25(11):1763–1768. doi: 10.1111/j.1440-1746.2010.06300.x
- Liu PT, Hwang AC, Chen JD. Combined effects of hepatitis B virus infection and elevated alanine aminotransferase levels on dyslipidemia. Metabolism. 2013;62(2):220–225. doi: 10.1016/j.metabol.2012.07.022
- Chiang CH, Lai JS, Hung SH, et al. Serum adiponectin levels are associated with hepatitis B viral load in overweight to obese hepatitis B virus carriers. Obesity (Silver Spring). 2013;21(2):291–296. doi: 10.1002/oby.20000
- Wong VW, Wong GL, Chu WC, et al. Hepatitis B virus infection and fatty liver in the general population. J Hepatol. 2012;56(3):533–540. doi: 10.1016/j.jhep.2011.09.013
- Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol. 2011;26(9):1361–1367. doi: 10.1111/j.1440-1746.2011.06801.x
- Li H, Zhu W, Zhang L, et al. The metabolic responses to hepatitis B virus infection shed new light on pathogenesis and targets for treatment. Sci Rep. 2015;5:8421. doi: 10.1038/srep08421
- Xu Z, Zhai L, Yi T, et al. Hepatitis B virus X induces inflammation and cancer in mice liver through dysregulation of cytoskeletal remodeling and lipid metabolism. Oncotarget. 2016;7(43):70559–70574. doi: 10.18632/oncotarget.12372
- Wu Y, Peng X, Zhu Y, et al. Hepatitis B virus X protein induces hepatic steatosis by enhancing the expression of liver fatty acid binding protein. J Virol. 2015;90(4):1729–1740. doi: 10.1128/JVI.02604-15
- Kim K, Kim KH, Kim HH, Cheong J. Hepatitis B virus X protein induces lipogenic transcription factor SREBP1 and fatty acid synthase through the activation of nuclear receptor LXRα. Biochem J. 2008;416(2):219–230. doi: 10.1042/BJ20081336
- Kang SK, Chung TW, Lee JY, et al. The hepatitis B virus X protein inhibits secretion of apolipoprtein B by enhancing the expression of N-acetylglucosaminyltransferase III. J Biol Chem. 2004;279(27):28106–28112. doi: 10.1074/jbc.M403176200
- Cheng YL, Wang YJ, Kao WY, et al. Inverse association between hepatitis B virus infection and fatty liver disease: a largescale study in populations seeking for checkup. PloS One. 2013;8(8):e72049. doi: 10.1371/journal.pone.0072049
- Ghalamkari S, Sharafi H, Alavian SM. Association of PNPLA3 rs738409 polymorphism with liver steatosis but not with cirrhosis in patients with HBV infection: Systematic review with metaanalysis. J Gene Med. 2018;20(1):e3001. doi: 10.1002/jgm.3001
- Kuo YH, Kee KM, Wang JH, et al. Association between chronic viral hepatitis and metabolic syndrome in southern Taiwan: a large populationbased study. Aliment Pharmacol Ther. 2018;48(9):993–1002. doi: 10.1111/apt.14960
- Banks DE, Bogler Y, Bhuket T, et al. Significant disparities in risks of diabetes mellitus and metabolic syndrome among chronic hepatitis C virus patients in the US. Diabetes Metab Syndr. 2017;11 Suppl 1:S153–S158. doi: 10.1016/j.dsx.2016.12.025
- Arain SQ, Talpur FN, Channa NA. A comparative study of serum lipid contents in pre and post IFN-alpha treated acute hepatitis C patients. Lipids Health Dis. 2015;14:117. doi: 10.1186/s12944-015-0119-x
- Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001;33(6):1358–1364. doi: 10.1053/jhep.2001.24432
- Negro F. Steatosis and insulin resistance in response to treatment of chronic hepatitis C. J Viral Hepat. 2012;19 Suppl 1:42–47. doi: 10.1111/j.1365-2893.2011.01523.x
- Hofmann S, Krajewski M, Scherer C, et al. Complex lipid metabolic remodeling is required for efficient hepatitis C virus replication. Biochim Biophys Acta Mol Cell Biol Lipids. 2018;1863(9):1041–1056. doi: 10.1016/j.bbalip.2018.06.002
- Chang ML. Metabolic alterations and hepatitis C: From bench to bedside. World J Gastroenterol. 2016;22(4):1461–1467. doi: 10.3748/wjg.v22.i4.1461
- Miyoshi H, Moriya K, Tsutsumi T, et al. Pathogenesis of lipid metabolism disorder in hepatitis C: polyunsaturated fatty acids counteract lipid alterations induced by the core protein. J Hepatol. 2011;54(3):432–438. doi: 10.1016/j.jhep.2010.07.039
- Blanchet M, Sureau C, Guévin C, et al. SKI-1/S1P inhibitor PF-429242 impairs the onset of HCV infection. Antiviral Res. 2015;115:94–104. doi: 10.1016/j.antiviral.2014.12.017
- Harris C, Herker E, Farese RVJr, Ott M. Hepatitis C virus core protein decreases lipid droplet turnover: a mechanism for core-induced steatosis. J Biol Chem. 2011;286(49):42615–42625. doi: 10.1074/jbc.M111.285148
- Sato S, Fukasawa M, Yamakawa Y, et al. Proteomic profiling of lipid droplet proteins in hepatoma cell lines expressing hepatitis C virus core protein. J Biochem. 2006;139(5):921–930. doi: 10.1093/jb/mvj104
- Ferguson D, Zhang J, Davis MA, et al. The lipid droplet-associated protein perilipin 3 facilitates hepatitis C virus driven hepatic steatosis. J Lipid Res. 2017;58(2):420–432. doi: 10.1194/jlr.M073734
- Meng Z, Liu Q, Sun F, Qiao L. Hepatitis C virus nonstructural protein 5A perturbs lipid metabolism by modulating AMPK/SREBP-1c signaling. Lipids Health Dis. 2019;18(1):191. doi: 10.1186/s12944-019-1136-y
- Camus G, Schweiger M, Herker E, et al. The hepatitis C virus core protein inhibits adipose triglyceride lipase (ATGL)-mediated lipid mobilization and enhances the ATGL interaction with comparative gene identification 58 (CGI-58) and lipid droplets. J Biol Chem. 2014;289(52):35770–35780. doi: 10.1074/jbc.M114.587816
- Abenavoli L, Masarone M, Peta V, et al. Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3. World J Gastroenterol. 2014;20(41):15233–15240. doi: 10.3748/wjg.v20.i41.15233
- Shi ST, Polyak SJ, Tu H, et al. Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. Virology. 2002;292(2):198–210. doi: 10.1006/viro.2001.1225
- Benga WJ, Krieger SE, Dimitrova M, et al. Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particles. Hepatology. 2010;51(1):43–53. doi: 10.1002/hep.23278
- Gong Y, Cun W. The Role of ApoE in HCV Infection and Comorbidity. Int J Mol Sci. 2019;20(8):2037. doi: 10.3390/ijms20082037
- Adinolfi LE, Restivo L, Zampino R, et al. Metabolic alterations and chronic hepatitis C: treatment strategies. Expert Opin Pharmacother. 2011;12(14):2215–2234. doi: 10.1517/14656566.2011.597742
- Huang CM, Chang KC, Hung CH, et al. Impact of PNPLA3 and IFNL3 polymorphisms on hepatic steatosis in Asian patients with chronic hepatitis C. PloS One. 2017;12(8):e0182204. doi: 10.1371/journal.pone.0182204
- Magri MC, Manchiero C, Prata TVG, et al. The influence of gene chronic hepatitis C virus infection on hepatic fibrosis and steatosis. Diagn Microbiol Infect Dis. 2020;97(2):115025. doi: 10.1016/j.diagmicrobio.2020.115025
- Liu Z, Que S, Zhou L, et al. The effect of the TM6SF2 E167K variant on liver steatosis and fibrosis in patients with chronic hepatitis C: a meta-analysis. Sci Rep. 2017;7(1):9273. doi: 10.1038/s41598-017-09548-9
- Yoon H, Lee JG, Yoo JH, et al. Effects of metabolic syndrome on fibrosis in chronic viral hepatitis. Gut Liver. 2013;7(14):469–474. doi: 10.5009/gnl.2013.7.4.469
- Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006;130(6):1636–1642. doi: 10.1053/j.gastro.2006.03.014
- Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61(1 Suppl):S58–S68. doi: 10.1016/j.jhep.2014.07.012
- Stevenson HL, Utay NS. Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era. Trop Dis Travel Med Vaccines. 2016;2:21. doi: 10.1186/s40794-016-0038-5